Skip to main
APGE

APGE Stock Forecast & Price Target

APGE Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Apogee Therapeutics Inc has experienced a notable increase in stock value, up approximately 19%, following favorable timeline updates regarding its lead antibody program APG777, with key clinical data results now anticipated for the first quarter of 2026. The company's potential to capture significant market share is underscored by the revenue success of its competitor, Dupixent, which generated over $14 billion in global sales in 2024, further projected to reach $20 billion in coming years due to ongoing market growth in the atopic dermatitis (AD) sector. Additionally, robust clinical data emerging from Phase II and Phase III studies suggests that APG777 may outperform existing therapies by leveraging better dosing and efficacy, supporting a positive outlook for future revenue opportunities in inflammatory and immunology indications.

Bears say

Apogee Therapeutics Inc. faces substantial risks that could significantly hinder its financial trajectory, primarily due to the potential for developmental setbacks in its pipeline programs, including unexpected safety signals and issues with efficacy. The company is particularly vulnerable to regulatory challenges, as failure to obtain necessary approvals or delays in clinical trials could severely limit its revenue generation capabilities. Moreover, operational hurdles such as commercialization difficulties and the inability to sustain research and development expenditures further exacerbate the negative outlook for the company's stock.

APGE has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Apogee Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Apogee Therapeutics Inc (APGE) Forecast

Analysts have given APGE a Strong Buy based on their latest research and market trends.

According to 9 analysts, APGE has a Strong Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Apogee Therapeutics Inc (APGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.